Continuous Aging of the Human DNA Methylome Throughout the Human Lifespan.

Johansson A, Enroth S, Gyllensten U. · 2013

Read Continuous Aging of the Human DNA Methylome Throughout the Human Lifespan. by Johansson A, Enroth S, Gyllensten U. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3695075.txt.

Introduction

Johansson, Enroth, and Gyllensten tracked how DNA methylation in white blood cells changes across the human lifespan, measuring nearly half a million sites in 421 people aged fourteen to ninety-four. Age touched almost a third of the sites: roughly sixty percent lost methylation with age, and forty percent gained it.

The gains were the more patterned side. Sites in CpG islands gained methylation more often, promoter sites were relatively stable, and gained sites clustered in genes for DNA binding, development, and brain differentiation. About twenty-three percent of the variation in methylation was explained by age alone. The authors link these steady shifts to the epigenetic side of aging and age-related disease.

Catalog record

CREATORJohansson A, Enroth S, Gyllensten U.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3695075

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Continuous Aging of the Human DNA Methylome Throughout the Human Lifespan By Åsa Johansson, Stefan Enroth, Ulf Gyllensten, Catherine M. Suter Published in: PLoS ONE DOI: 10.1371/journal.pone.0067378 ABSTRACT DNA methylation plays an important role in development of disease and the process of aging. In this study we examine DNA methylation at 476,366 sites throughout the genome of white blood cells from a population cohort (N = 421) ranging in age from 14 to 94 years old. Age affects DNA methylation at almost one third (29%) of the sites (Bonferroni adjusted P-value <0.05), of which 60.5% becomes hypomethylated and 39.5% hypermethylated with increasing age. DNA methylation sites that are located within CpG islands (CGIs) more often become hypermethylated compared to sites outside an island. CpG sites in promoters are more unaffected by age, whereas sites in enhancers more often becomes hypo- or hypermethylated. Hypermethylated sites are overrepresented among genes that are involved in DNA binding, transcription regulation, processes of anatomical structure and developmental process and cortex neuron differentiation (P-value down to P = 9.14*10−67). By contrast, hypomethylated sites are not strongly overrepresented among any biological function or process. Our results indicate that the 23% of the variation in DNA methylation is attributed chronological age, and that hypermethylation is more site-specific than hypomethylation. It appears that the change in DNA methylation partly overlap with regions that change histone modifications with age, indicating an interaction between the two major epigenetic mechanisms. Epigenetic modifications and change in gene expression over time most likely reflects the natural process of aging and variation between individuals might contribute to the development of age-related phenotypes and diseases such as type II diabetes, autoimmune and cardiovascular disease. INTRODUCTION Epigenetics is used to denote the regulation of gene transcription that cannot be attributed to sequence variation in the DNA. Although the term epigenetics includes a number of different mechanisms, DNA methylation and histone modification are most commonly discussed. DNA methylation in mammals appears to be specific to cytosine, predominantly to CpG (cytosine-phosphate-guanine) dinucleotides. In promoter regions, CpG sites are often clustered in CpG islands (CGIs) were methylation is believed to repress gene expression [1]. Even small changes in the methylation of a promoter region can introduce stable changes in gene expression, leading to silencing of a gene [2], [3]. Recently, different array- and sequence-based techniques for measuring of the genome-wide DNA methylation pattern have been developed, and the different techniques have yielded concordant results [4], [5]. A number of environmental factors, such nutrition status, exposure to drugs, pesticides and other compounds, have been found to alter the epigenome [6]. A number of genomic regions have been proposed to be differentially methylated between MZ twins discordant for disorders such as schizophrenia [7], caudal duplication anomalies [8], bipolar disorder [9], and systemic lupus erythematosus [10]. More comprehensive genome-wide studies of methylation using larger sample sizes have shown that changes in DNA methylation pattern in the human brain and in blood leukocytes [11]–[13] and in cord blood from newborn compared to peripheral blood mononuclear in elderly [14], is highly correlated with the chronological age. Although most studies performed are based on a small number of individuals or methylation sites, they point to the importance of epigenetic modifications in the process of aging. The use of novel methylation assays with a higher genomic resolution and larger sample sizes spanning a wider age-range will greatly increase our understanding of the relationship between the DNA methylation level and chronological age. In this study we evaluate the effect of chronological age on DNA methylation in 421 individuals aged 14 to 94 years, in which DNA methylation status in white blood cells has been determined at more than 475,000 sites distributed throughout the genome [15]. MATERIALS AND METHODS Study Population The Northern Sweden Population Health Study (NSPHS) was initiated in 2006 to provide a health survey of the population in the Parishes of Karesuando and Soppero, County of Norrbotten, and to study the medical consequences of lifestyle and genetics. This parish has about 3000 inhabitants who meet the eligibility criteria in terms of age (>15 years) of which 1069 individuals participated in the study. Studies of populations such as NSPHS can be of great value for studying health effects of lifestyle and genetic factors. In addition, rural individuals usually live in the same environment over an extended time period, which increases the health effects of their lifestyle but also make them optimal for studying the long-term lifestyle and environmental effect on DNA methylation. For each participant in the NSPHS, blood samples were taken and immediately frozen and stored at −70 C. Genomic DNA for methylation analyses was extracted from previously frozen peripheral blood leukocytes using a phenol:chloroform protocol. More information about the NSPHS has been published previously [16]. The NSPHS study was approved by the local ethics committee at the University of Uppsala (Regionala Etik prövnings nämnden, Uppsala, Dnr 2005:325) in compliance with the Declaration of Helsinki. All participants gave their written informed consent to the study including the examination of environmental and genetic causes of disease. In case the participant was not full age, a legal guardian signed additionally. The procedure which was used to obtain informed consent and the respective informed consent form has been recently discussed in the light of present ethical guidelines [17]. Since we are working with a study cohort from a limited area, deposition of the raw data might allow for person identification. Due to concerns regarding patient privacy and protection, we are therefor unable to deposit the raw data to a central repository. However, data will be made available to researchers upon request. [17]. Determination of DNA Methylation Status Genomic DNA was bisulfite-converted using an EZ DNA methylation Kit (ZYMO research) according to the manufacturer's recommendations. The methylation status of the genomic DNA was then assessed using he Human Methylation450 BeadChip, (Illumina, San Diego, USA) according to the standard protocol. Analysis of the raw data was performed using Illumina GenomeStudio 2009, using the recommended settings from Illumina and the HumanMethylation450_15017482_v.1.2.bpm manifest file. The quality control (QC) parameters recommended by Illumina were used (Individual Probe Call rate >0.98, marker detection P-value < = 0.01). Transcription Profiling Data Transcription profiling data from whole blood for 99 healthy US controls individuals from the PREDICT trial (http://www.clinicaltrials.gov , accession number: NCT00500617) together with information of gender and birth date were downloaded from the ArrayExpress database (www.ebi.ac.uk/arrayexpress, accessed 14 October, 2012) under accession number E-GEOD-20686. This data were produced using Agilent Whole Human Genome Microarray 4×44K 014850 G4112F, (Agilent Technologies Inc, Americas). Description on sample preparation and processing of transcription data has been published previously [18]. Gene annotations for the probes were obtained using the Ensembl database (http://www.ensembl.org, accessed –14, October 2012). Statistic Analyses of DNA Methylation Data All statistic analyses were performed using the stats library of R version 2.15.0 [19]. Methylation values were reported as average beta values, which represent the ratio of array intensity signal obtained from the methylated beads over the sum of methylated and unmethylated beads (or the fraction of DNA fragments that are methylated at a specific site for an individual). Beta values for each marker were fitted to a linear model using chronological age, sex and bmi as covariables.

Read the complete text